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ABSTRACT
Rosacea is a chronic inflammatory skin
condition that commonly presents with
persistent facial erythema with or without the
coincident presence of flushing, telangiectasias,
inflammatory papules or pustules, phymatous
changes, or ocular involvement. Patients often
present with a constellation of various signs and
symptoms of the disease, and an individualized
treatment plan should be tailored to a patient’s
unique clinical presentation. Previously
available medications for rosacea have all
targeted the inflammatory erythematous
papules and pustules frequently associated
with the disease, leaving a therapeutic gap for
the common manifestation of persistent facial
erythema. Brimonidine tartrate 0.33% gel was
approved by the US Food and Drug
Administration in August 2013 as the first
medication available for the topical treatment
of persistent facial erythema associated with
rosacea. Brimonidine gel is a highly selective a2-
adrenergic receptor agonist with potent
vasoconstrictive effects, which leads to
significant reduction of persistent facial
erythema in the majority of patients when
applied once daily. Based on large-scale
clinical trials and post-marketing reports,
brimonidine gel has maintained a good safety
profile with a minority of patients experiencing
adverse effects from its use, most of which are
cutaneous in nature, mild-to-moderate in
degree, occur early after initiation of
treatment, often resolve spontaneously with
continued use, and generally resolve after
discontinuation of use. Among the reported
adverse effects, two distinct manifestations of
worsened erythema have been described.
Brimonidine gel can be integrated into a
treatment regimen along with concomitant
therapies for facial papules and pustules with
no increased risk of adverse events with
combination therapy. Education about
optimal application methods, setting
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reasonable expectations for treatment, and
minimizing inflammation are important
factors for the successful use of brimonidine
gel as part of a patient’s overall rosacea
treatment regimen.
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INTRODUCTION
Rosacea is a chronic condition of the facial skin
that affects approximately 16 million people in
the United States [1]. Clinically, it is
characterized by flushing, persistent facial
erythema, telangiectasias, papules, pustules,
edema, and/or phymatous changes. It can
affect the facial skin as well as the eyes. Most
experts currently view rosacea as a chronic
inflammatory skin disease with a spectrum of
clinical features that can wax and wane over
time and that often overlap several of the
different clinical subtypes [1–3]. According to
the National Rosacea Society Expert Committee
in 2002, rosacea is grouped into the four
following clinical subtypes:
erythematotelangiectatic (ETR), papulopustular
(PPR), phymatous, and ocular [4]. ETR
characteristically presents with flushing and
persistent facial erythema, while PPR usually
presents with inflamed papules and pustules. In
the phymatous subtype, there is thickening of
the skin as well as nodule formation causing
irregularity of the surface of the facial skin.
Ocular rosacea typically involves irritation or a
burning sensation associated with redness of
the eyes and is considered a clinical entity that
is distinct from the three facial rosacea
subtypes; however, it can be present in about
20% of those patients [4].
Although the four subtypes are characterized
by different common signs and symptoms,
patients often present with a range of
symptoms that overlap several subtypes; and,
transient and persistent facial erythema is often
observed in all four subtypes of rosacea [5]. For
the purposes of this review, ETR will be the
subtype most frequently discussed. Facial
redness is an extremely common
manifestation of rosacea and presents a
significant challenge for treatment. Vascular
and inflammatory mechanisms are both
involved in the clinical manifestations of this
problem [6, 7]. PPR exhibits lesional or
perilesional erythema that is distinct from
generalized vascular erythema [8–10]. It is
believed that the vascular mechanisms
contributing to facial erythema in rosacea can
be transient or persistent [8]. Flushing
associated with rosacea likely occurs via a
different mechanism than that of generalized
erythema; but, flushing should also be
considered distinct from physiologic blushing,
which occurs involuntarily in response to
emotional stimuli.
There is no cure for rosacea, and treatments
are intended to control the signs and symptoms
that define the disease [11]. Until recently, there
have been only five medications approved by
the US Food and Drug Administration (FDA) for
the treatment of rosacea, and all of these are
intended to treat the inflammatory lesions of
the PPR subtype [12]. Metronidazole is a
synthetic antimicrobial, antioxidant, and anti-
inflammatory agent recommended by the
American Acne and rosacea Society (AARS) for
the topical treatment of inflammatory lesions
and transient erythema [12, 13]. Azelaic acid is a
naturally occurring saturated dicarboxylic acid
with anti-inflammatory, antioxidant, and
antimicrobial effects recommended by the
AARS for the topical treatment of
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inflammatory papules and pustules of mild to
moderate rosacea [12, 14]. Sulfur has
keratolytic, antifungal, and antibacterial
properties, and sodium sulfacetamide–sulfur is
used for the topical treatment of inflammatory
papular lesions in rosacea [15, 16]. Ivermectin is
a broad-spectrum anti-parasitic medication also
with anti-inflammatory effects that is thought
to kill Demodex mites residing in the
pilosebaceous units of patients with PPR and
has recently been approved for topical use [17].
Lastly, a sub-antimicrobial dose of the oral
medication doxycycline 40 mg modified
release once daily is approved for the
treatment of inflammatory lesions of rosacea
in patients at least 18 years of age [12]. All of
these approved medications target the
inflammatory lesions (papules and pustules) of
rosacea. Because of this there has been a gap in
treatment options available for the persistent
facial erythema of rosacea that is most
pronounced in ETR but observed in all four
subtypes of the disease.
The US FDA approved brimonidine tartrate
0.33% gel in August 2013 for the topical
treatment of persistent (nontransient) facial
erythema of rosacea in adults 18 years of age
and older. This is the first and currently only
approved topical treatment for the persistent
erythema of rosacea [18]. Brimonidine is a
highly selective a2-adrenergic receptor agonist
with potent vasoconstrictive effects [19].
Another a-adrenergic receptor agonist,
oxymetazoline (a selective a1 agonist and
partial a2 agonist), is currently under
investigation in phase 3 clinical trials for the
topical treatment of facial erythema of rosacea
[20]. This review article will discuss the
mechanism of action of topical brimonidine
gel in the treatment of persistent facial
erythema in rosacea, the clinical data leading
to its FDA approval for this indication, as well as
its approved dose, administration, safety profile,
reported adverse effects, and role in
combination treatment for rosacea.
This article is based on previously conducted
studies and does not involve any new studies of




Brimonidine is a highly selective a2-adrenergic
receptor agonist and is 1000-fold more selective
for the a2-adrenergic receptor than the a1-
adrenergic receptor [21]. This medication was
previously used as a topical treatment for open-
angle glaucoma and was more recently found to
be effective in controlling the diffuse facial
erythema of rosacea. A recent study by Piwnica
et al. demonstrated high selectivity of
brimonidine specifically for the a2-A
adrenergic receptor with minimal off-target
effects from interactions with the a1-A, a1-B,
a2-B, and a2-C adrenergic receptors [21].
Through this specific action on post-synaptic
endothelial a2 receptors, brimonidine was
shown to be a potent vasoconstrictor of
human subcutaneous blood vessels with a
diameter of less than 200 lm, and it was also
demonstrated to block the vasodilatory effect of
capsaicin [21]. Additionally, the anti-
inflammatory nature of brimonidine in skin
has been demonstrated in mouse ear models of
inflammation, in which it was found to inhibit
experimentally induced ear edema compared to
a matched vehicle control [21].
Brimonidine is metabolized extensively by
the liver, and the major route of its elimination
and that of its metabolites is urination excretion
[4]. In a recent study by Benkali et al., detectable
systemic exposure occurred in 22–79% of
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patients who received topical brimonidine gel
daily for 29 days with increasing concentrations
from 0.18–0.5%, respectively, and with average
peak serum concentrations ranging from 13 to
25 pg/mL [22]. This very low level of systemic
absorption was lower than that of brimonidine
tartrate 0.2% ophthalmic solution three times
daily, which yielded a mean peak serum
concentration of 54 pg/mL.
PHASE II CLINICAL TRIAL DATA
The pharmacodynamics and safety of three
concentrations (0.07, 0.18, and 0.5%) of
topical brimonidine gel were evaluated in a
first phase II randomized, double-blind,
parallel-group, vehicle-controlled study (study
A) [23]. This first study enrolled 122 patients (30
men, 92 women) and was conducted at 5
centers in the United States. The clinician’s
erythema assessment (CEA) and patient’s self-
assessment (PSA) scales were used to grade
improvements in facial erythema at specified
time points (Table 1). Brimonidine was effective
in reducing erythema for the first 12 h in a dose-
dependent manner, with the greatest effect seen
at a concentration of 0.5% [23]. All three
concentrations were considered safe and were
well tolerated.
A second phase II study (study B, or phase
IIb) enrolled 269 patients (52 men, 217 women)
at 17 centers in the United States and evaluated
topical brimonidine gel at concentrations of
0.18% and 0.5% [23]. Once-daily topical
administration demonstrated rapid onset,
sustained duration of action, and a dose-
dependent effect with maximum benefit at
0.5% with no significant difference in the
number of patients experiencing a perceived
adverse effect compared to that in the vehicle
control group [23]. During the 4 weeks of the
study and the 4-week follow-up period after the
study, there was no tachyphylaxis (loss of
previous noted effect) or rebound (worsening
of the persistent facial erythema compared to
baseline) observed. The aim of these two studies
was to determine the optimal dose regimen for
the treatment of moderate to severe erythema
associated with rosacea, and based on the
results the concentration of 0.5% brimonidine
gel was selected for phase III evaluation [23].
PHASE III CLINICAL TRIAL DATA
The safety and efficacy of brimonidine gel in the
treatment of rosacea were evaluated in two
large-scale, multicenter, randomized, double-
blind, parallel-group, vehicle-controlled phase
III studies as well as a long-term open-label
safety study [19, 24]. The first phase III study
enrolled 260 patients (54 men, 206 women) in
15 centers in the US and in Canada. Patients
with moderate to severe erythema due to
rosacea were randomized to receive topical
Table 1 Clinician’s erythema assessment (CEA) and patient’s self-assessment (PSA)
Scores CEA PSA
0, Clear Clear skin with no signs of erythema Clear of unwanted redness
1, Almost clear Almost clear; slight redness Nearly clear of unwanted redness
2, Mild Mild erythema; deﬁnite redness Somewhat more redness than I prefer
3, Moderate Moderate erythema; marked redness More redness than I prefer
4, Severe Severe erythema; ﬁery redness Completely unacceptable redness
174 Dermatol Ther (Heidelb) (2015) 5:171–181
brimonidine 0.5% gel or a vehicle control once
daily for 4 weeks with a 4-week follow-up
period. A second phase III study enrolled 293
patients (80 men, 213 women) with the same
study design and the same concentration of
brimonidine 0.5% compared to vehicle control
[19].
As in the phase II studies, the CEA and PSA
scales were used to grade improvements in
facial erythema at specified time points in the
studies. The primary endpoint for both phase III
studies was defined as a 2-grade improvement in
both the CEA and PSA at 3-h intervals over the
first 12-h post-treatment on days 1, 15, and 29,
with a 1-grade improvement considered a
clinically meaningful result. The secondary
endpoint was defined as a 1-grade
improvement from baseline in both the CEA
and PSA at 30 min after application on day 1,
which corresponded to the onset of action.
Compared to the vehicle control, once-daily
topical brimonidine 0.5% gel demonstrated a
significant reduction in facial erythema based
on both the CEA and the PSA 30 min after
application on day 1, and this significant effect
was again demonstrated 30 min after
application on days 15 and 29 [19]. On day
29, significantly more patients had a 2-grade
improvement on both the CEA and PSA at 3, 6,
9, and 12 h after application of brimonidine
0.5% gel compared to vehicle control [19].
Once-daily brimonidine 0.5% gel was
considered safe and well tolerated in both
phase III studies with the incidence of adverse
events (AEs) being 29.5% compared to 25.2%
for the vehicle control in the first study and
33.8% compared to 24.1% for the vehicle
control in the second study [19]. The
incidence of AEs related to brimonidine was
11.6% compared to 5.3% for the vehicle control
in the first study and 9.5% compared to 9.7%
for the vehicle control in the second study [19].
As seen in the phase IIb study as well as during
the 4-week study period and the 4-week follow-
up period for both phase III studies, there was
no tachyphylaxis or rebound erythema (as it
was defined in the clinical trials) observed for
the use of topical brimonidine gel, with the
exception of isolated cases of worsening
erythema and/or flushing [19]. These isolated
cases were not recorded as ‘‘rebound.’’
LONG-TERM SAFETY STUDY
The long-term safety and efficacy of
brimonidine 0.5% once daily were evaluated
in a 12-month, open-label, multicenter study
[24]. There were 449 patients enrolled in the
study (113 men, 336 women), of which 335
(74.6%) completed at least 6 months of once-
daily treatment and 279 (62.1%) completed
12 months of treatment with follow-up (a total
of 345 subject-years of exposure) [24]. The study
included 8 visits: screening, baseline at day 1,
follow-up at week 1, and repeat follow-up at
months 1, 3, 6, 9, and 12. Safety tests and
measures included vital signs, intraocular
pressure, physical exams, blood chemistry,
hematology, and urinalysis. Treatment
measures included the CEA, PSA, the 5-point
Telangiectasia Grading Assessment scale from 0
(clear) to 4 (severe), and manual count of
inflammatory lesions present (sum of papules,
pustules, and nodules). AEs were also reported
and assessed throughout the 12-month study.
AEs were most commonly reported during
the first quarter (41.9% total patients with AEs;
21.4% with AEs related to brimonidine use),
with a substantial decline by the second quarter
(24.6% total AEs; 7.6% related AEs), followed by
a relative decline for the remainder of the study
(19.5% total AEs in the fourth quarter; 4.2%
related AEs in the fourth quarter) [24]. The most
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common related AEs observed were flushing
(9.1%), worsening of erythema (6.5%),
worsening of rosacea (3.6%), contact
dermatitis (2.2%), and pruritus (2.0%) [24].
The majority of these were mild or moderate
in intensity. Approximately 30% of patients
received concomitant therapies for their facial
papules and pustules related to rosacea, and
there was no observed increased risk for AEs
from combination therapy with topical
brimonidine treatment [24].
In terms of efficacy, the 12-month study
corroborated the results of the phase II and
phase III trials with a durable beneficial effect in
the treatment of moderate to severe facial
erythema associated with rosacea without any
observed tachyphylaxis [24]. Long-term follow-
up studies are needed to examine whether there
is chronic remodeling of vasculature or durable
modification of neurovascular regulation with
prolonged daily use that may alter baseline





Brimonidine gel is intended to be applied as a
pea-sized amount once daily to each of five
regions of the face: the central forehead, chin,
nose, and each cheek, with even application as a
thin layer avoiding the eyes and lips. Each gram
of gel contains 5 mg of brimonidine tartrate,
equivalent to 3.3 mg of brimonidine-free base.
According to the FDA, brimonidine tartrate
topical gel should be used with caution in
patients with depression, cerebral or coronary
artery insufficiency, Raynaud’s phenomenon,
orthostatic hypotension, thrombangiitis
obliterans, scleroderma, or Sjo¨gren’s syndrome
due to concern for possible potentiation of
vascular insufficiency in these patients. It
should also be used with caution in patients
with severe or unstable cardiovascular disease,
as a2-adrenergic agonists can lower blood
pressure. These are theoretical risks to
consider, and the clinical trials mentioned
above demonstrate a high safety profile for
this medication. It is, however, important to
keep brimonidine gel out of reach of children as
two young children of a research subject in one
of the clinical trials experienced serious adverse
reactions following accidental ingestion. This
included lethargy, respiratory distress with
apneic episodes requiring intubation, sinus
bradycardia, confusion, psychomotor
hyperactivity, and diaphoresis. Both children
made a full recovery within 24 h with no
sequelae [32].
The most common AEs were cutaneous and
mild or moderate in degree. They include
flushing (9.1%), worsening erythema (6.5%),
worsening of papules and pustules of rosacea
(3.6%), burning sensation of the skin (3.3%),
skin irritation (3.1%), contact dermatitis (2.2%),
and pruritus (2.0%) [24]. Allergic contact
dermatitis was reported in approximately 1%
of patients, and results from patch testing of
two clinical trial subjects revealed that one was
sensitive to brimonidine tartrate and the other
was sensitive to phenoxyethanol (preservative)
[32, 33]. Potential medication interactions
include antihypertensives, cardiac glycosides,
central nervous system depressants, and
monoamine oxidase inhibitors. Topical
brimonidine tartrate gel is pregnancy category
B, has unknown excretion in human breast milk
but has been shown to be excreted in breast
milk in animal studies, and is not intended for
use in children and should be kept out of their
reach [32].




There have been recent case reports of
exaggerated recurrence of erythema (documented
in the literature as ‘‘rebound’’) associated with
the use of topical brimonidine tartrate gel [25,
26]. One case described a 29-year-old female
with ETR associated with persistent erythema
and occasional flushing who had a favorable
reduction in baseline erythema within 1–2 h
after application that lasted for 10–12 h but was
followed by an exaggerated recurrence of erythema
past baseline, which lasted for 12–14 h and was
self-limited [25]. This occurred again in the
same patient with the two subsequent
applications, and she then stopped using the
medication. Another report outlined three
patient cases in which persistent erythema was
favorably reduced within 1–6 h after application
followed by an exaggerated recurrence of erythema
past baseline at 12 h after application that was
associated with a burning sensation [26]. This
lasted an additional 12 h and was self-limited
with spontaneous resolution within 1 day, but
it was reported to recur and worsen with
continued use in these individuals. The cases
reported by Routt et al. also involved worsening
of erythema after the first application of
brimonidine gel [26]. This relatively
immediate reaction (with or without
additional symptoms such as burning) was
previously suggested to be considered a
paradoxical erythema, which was defined as
redness appearing within 3–6 h after
application of brimonidine [27]. This should
be considered as a different reaction than the
exaggerated recurrence of erythema, and it can be
more bothersome for patients since the
erythema occurs during the time period when
he or she most wanted to be free of facial
redness.
Similar cases as those mentioned in the
reports above have been reported to the
manufacturer of brimonidine gel, Galderma
Laboratories, L.P., as reports of ‘‘condition
aggravated’’ or ‘‘rebound effect’’ as part of post-
marketing pharmacovigilance analysis. In these
reports from drug launch in August 2013
through April 2014, the most frequently
associated symptoms were erythema, flushing,
burning sensation or skin warmth, and rarely,
skin pain [27]. Dermatitis, pruritus, swelling,
and pallor were reported in less than 10% of
these cases [27]. These reactions were reported
to occur most often in the first 1 week of
initiation of therapy [27]. There is usually
rapid resolution of these AEs with only rare
reports of paradoxical erythema or exaggerated
recurrence of erythema with the aforementioned
associated symptoms lasting weeks, and in a
majority of cases the AE improved or resolved
after stopping brimonidine [25–27].
Similar to the trend in the post-marketing
pharmacovigilance data where it was observed
that paradoxical erythema and exaggerated
recurrence of erythema decreased dramatically
after 1 week of use, erythema and a burning
sensation were infrequent AEs of topical
brimonidine use during the clinical trials; and,
the incidence of all AEs decreased from quarter
one through quarter four over the first
12 months of daily use [24].
EXPERIENCES IN CLINICAL
PRACTICE
As an ophthalmic solution, brimonidine
tartrate has a well-established safety and
efficacy record with nearly 20 years of clinical
use for the treatment of open-angle glaucoma
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[28, 29]. After recent clinical trials have
demonstrated its safety and efficacy in a gel
formulation for the treatment of persistent
facial erythema associated with rosacea, the
FDA approved brimonidine tartrate 0.33%
topical gel in August 2013. Clinical trial data,
long-term pharmacovigilance data, and
individual case reports in the literature
describe infrequent adverse effects associated
with use of brimonidine gel, most of which are
cutaneous, mild, and reversible upon
discontinuation of use, and among which are
the occurrence of paradoxical erythema and
exaggerated recurrence of erythema.
Tanghetti et al. recently published panel
recommendations in 2015 regarding the
optimal use of brimonidine gel in the
management of rosacea [27]. First among these
recommendations, one should assess the
clinical features of rosacea and rule out
alternative diagnoses followed by the
development of a treatment plan that targets
the different clinical symptoms present in each
individual patient [27, 30]. Second, each patient
should be educated about triggers such as UV
light, heat, spicy foods, red wine, among others;
and, it should be clearly explained that
brimonidine will not completely negate the
erythema-inducing effects of these triggers, nor
will it eliminate papules, pustules, or
telangiectasias associated with rosacea or
provide a cure for facial erythema associated
with rosacea [19, 24, 27, 30]. Steps should be
taken to minimize inflammation associated
with rosacea, including the use of gentle
cleansers, moisturizers or skin barrier repair
products, and regular photoprotection [27,
31]. Inflammatory lesions associated with
rosacea should be treated with an appropriate
agent when they are present because these, as
well as perilesional erythema and
telangiectasias, may be more visible following
the use of brimonidine [27, 30]. Appropriate
expectations should be set, including discussion
that there is a risk of worsening of facial redness
in 10–20% of patients, that this worsening of
redness usually occurs within the first 2 weeks
of treatment when it does occur, and that this
adverse effect generally resolves spontaneously
within 12–24 h after discontinuation of use
[27]. Tanghetti et al. suggested the potential
use of oral acetyl salicylic acid 80–500 mg/day,
ibuprofen, or naproxen for burning sensations
associated with worsening of facial redness, an
antihistamine if swelling or pruritus is present, a
cool compress for facial warmth, or a topical
corticosteroid or calcineurin inhibitor for any of
these associated symptoms [27]. Allergic or
irritant contact dermatitis should be suspected,
despite its rare occurrence, if facial redness first
appears greater than 3–4 months after initiation
of therapy [27]. Lastly, it is important to educate
patients about optimal application of
brimonidine: start with a small pea-sized
amount spread thinly once every day, in some
cases on a test patch prior to application of the
entire face, with gradual increases in the
amount applied to achieve the desired effect
[27]. Patients should continue use of their facial
moisturizer along with the initiation of
brimonidine gel, and the first application
should be on a day when the patient can stay
home to observe the effects [27]. It is important
to explain that since brimonidine gel has been
studied and approved based on once-daily use,
it is difficult to predict its side effect profile
when used intermittently [27].
One of the authors of this paper (SMJ) has
successfully integrated the use of brimonidine
gel for the treatment of persistent facial
erythema of rosacea by reinforcing good skin
hygiene with all patients suffering from rosacea.
This includes using only gentle cleansers, using
only the fingers to cleanse the face, and
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avoiding the use of toners, astringents,
exfoliants, washcloths, or other abrasive
products. Liberal use of bland moisturizers and
sun protection is also encouraged. When
initiating treatment with brimonidine, we
advise starting with a small pea-sized drop to
cover the entire face. Each day the size of the
drop may be increased slightly until the desired
clinical result is achieved. We also do not
initiate use of brimonidine in the same month
as initiating use with a topical retinoid or
retinol since these can all affect the already
disrupted cutaneous barrier in a patient
suffering with rosacea.
CONCLUSION
Rosacea is a common chronic inflammatory
condition of the facial skin with a spectrum of
clinical features that can wax and wane over
time. Many of these clinical features overlap in
the four recognized clinical subtypes of the
disease [1, 2]. Persistent facial erythema is a
very common and difficult to treat
manifestation of many cases of rosacea, and
until recently represented a significant gap in
the therapeutic management of the disease.
Flushing is a distinct symptom of rosacea that
involves rapid-onset superficial cutaneous
vasodilatation in response to emotional
triggers, whereas transient or persistent
erythema may be a result of the multifactorial
inflammatory process promoting
vasodilatation and neovascularization.
Brimonidine tartrate topical gel is the first
approved agent for the treatment of facial
erythema associated with rosacea and acts
through vasoconstriction of small caliber
subcutaneous blood vessels via specific
agonism of the post-synaptic a2A-adrenergic
receptor on endothelial cells.
Significant improvement in erythema is
experienced in the majority of patients with
once-daily topical application with few
experiencing mild to moderate cutaneous
adverse effects that are often not persistent
with continued use [34]. This provides
clinicians with a safe and effective treatment
modality for this previously difficult to treat
manifestation of rosacea, and it has been shown
to be safely used in combination with other
therapeutics targeting the inflammatory lesions
of the disease. Currently this is a short-term
symptomatic treatment with significant
beneficial effects that wear off by around 12 h
after application. Further studies are needed to
address the hypothetical question that
continued long-term use of this medication
may permanently alter neurovascular
mechanisms behind persistent erythema in
rosacea and possibly alter the course of this
clinical manifestation over time.
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